The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...

Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and ...

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

In a study published in the journal Nucleic Acid Research, a research team at Karolinska Institutet has performed a ...

We will release our fourth-quarter 2025 results on Wednesday, Jan. 28, 2026, and webcast a conference call to discuss results.Key Takeaways:AT&T will release its fourth-quarter 2025 results on Jan.

IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) ...

A new study finds that taking arginine orally may lower amyloid buildup and neuroinflammation, suggesting a safe, low-cost ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

A build-up of sticky proteins in the brain is a key hallmark of Alzheimer's, thought to be closely linked to the disease's progression.

Groundbreaking research led by the University of Alberta challenges the belief that mad cow disease is caused only by ...

Amino acid arginine has shown promise in reducing the buildup of amyloid-beta plaques in animal models of Alzheimer's disease ...

A new study suggests that arginine, a common amino acid, may help reduce the brain plaques associated with Alzheimer’s ...